FDA Approves Hovilpri for Immunocompromised Adults with Treatment-Resistant HSV Lesions

For sponsors developing antivirals in refractory or immunocompromised populations, the FDA's approval of Hovilpri (pritelivir) tablets establishes a clinical and regulatory reference point that will be difficult to ignore. The agency cleared the drug on 9 October 2026 for immunocompromised adults with mucocutaneous herpes simplex virus (HSV) lesions unresponsive to acyclovir, valacyclovir, or famciclovir, a population with limited therapeutic options and a documented history of viral resistance to nucleoside analogues.

The approval rested on the PRIOH-1 Phase 3 Trial (Part C; NCT 03073967), a randomized, open-label, comparator-controlled superiority study enrolling 101 immunocompromised adults. The trial's primary endpoint, proportion of participants with complete lesion healing within 28 days, favoured pritelivir at 63% versus 34% for investigator-selected standard-of-care agents. The enrolled population spanned a clinically heterogeneous range of immunosuppressive conditions: hematologic malignancies, hematopoietic stem-cell transplantation, HIV infection, autoimmune and inflammatory diseases, non-hematologic malignancies, and solid-organ transplantation. That breadth will inform how prescribers and protocol designers define eligibility in future antiviral studies targeting similar cohorts.

From a regulatory strategy perspective, the priority review designation signals FDA's assessment that pritelivir addresses an unmet medical need in a serious condition, a designation that carries submission timeline implications and, for competing sponsors, a signal about where the agency is directing review resources in the antiviral space. Pritelivir's mechanism differs from approved nucleoside analogues, targeting the viral helicase-primase complex rather than DNA polymerase, which is directly relevant to its activity in acyclovir-resistant HSV strains.

The safety profile reported in the prescribing information is notable for its simplicity at this stage: headache was the most common adverse reaction. QA and pharmacovigilance teams preparing post-marketing surveillance frameworks should, however, review the prescribing information closely for flagged drug-drug interactions, given the polypharmacy burden typical in the approved patient population.

The 28-day primary assessment window, extendable to 42 days for lesions showing improvement, represents a trial design decision that clinical operations teams will reference when constructing endpoints for similarly protracted dermatological or mucosal endpoints in immunocompromised subjects.

Regulatory affairs leads tracking the antiviral pipeline should note that the PRIOH-1 superiority design, combined with the priority review pathway, now constitutes a documented precedent for HSV indication submissions in treatment-refractory, immunocompromised populations.